Context Therapeutics Inc. SEC filings CNTX
Context Therapeutics Inc. has 307 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure
|
Aug 5, 2026 | Aug 5, 2026 |
| 8-K |
Current report
Listing notice
|
Jul 31, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Jun 26, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 18, 2026 | May 14, 2026 |
| 8-K |
Current report
Other events
|
May 1, 2026 | Apr 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 2, 2026 | Apr 2, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 23, 2026 | Mar 23, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Mar 13, 2026 | Mar 11, 2026 |
| 8-K |
Current report
Other events
|
Feb 27, 2026 | Feb 24, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 8, 2026 | Jan 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 24, 2025 | Oct 24, 2025 |
| 8-K |
Current report
Other events
|
Oct 20, 2025 | Oct 17, 2025 |
| 8-K |
Current report
Listing notice
|
Sep 2, 2025 | Aug 28, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 12, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 2, 2025 | Jun 2, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 9, 2025 | Apr 9, 2025 |
| 8-K |
Current report
Listing notice
|
Feb 28, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jan 14, 2025 | Jan 14, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jan 13, 2025 | Jan 10, 2025 |
| 8-K |
Current report
Other events
|
Dec 23, 2024 | Dec 23, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Dec 2, 2024 | Dec 2, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure, Other events
|
Sep 23, 2024 | Sep 23, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Sep 17, 2024 | Sep 17, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 4, 2024 | Sep 4, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Jul 10, 2024 | Jul 9, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2024 | Jun 13, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure, Other events
|
May 2, 2024 | May 1, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 1, 2024 | Apr 1, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Mar 21, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Mar 6, 2024 | Feb 29, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 31, 2023 | Oct 31, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 7, 2023 | Aug 7, 2023 |
| 8-K |
Current report
Other events
|
Jun 20, 2023 | Jun 15, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 2, 2023 | May 31, 2023 |
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Regulation FD disclosure
|
Mar 22, 2023 | Mar 17, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Feb 6, 2023 | Feb 6, 2023 |
| 8-K |
Current report
Listing notice
|
Jan 27, 2023 | Jan 24, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 4, 2023 | Jan 4, 2023 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2022 | Dec 7, 2022 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 1, 2022 | Nov 29, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 27, 2022 | Sep 27, 2022 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Aug 2, 2022 | Aug 1, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 3, 2022 | Jun 2, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2022 | Mar 23, 2022 |
| 8-K |
Current report
Other events
|
Jan 10, 2022 | Jan 10, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Jan 5, 2022 | Jan 1, 2022 |
| 8-K |
Current report
Other events
|
Dec 6, 2021 | Dec 6, 2021 |
| 8-K |
Current report
Results of operations
|
Dec 2, 2021 | Dec 2, 2021 |
| 8-K |
Current report
Officer or director change
|
Nov 1, 2021 | Nov 1, 2021 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Other events
|
Oct 22, 2021 | Oct 22, 2021 |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Philadelphia, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1842952
- Former names
- Context Therapeutics LLC (until May 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.